GlassScriptPhysician profile
Mikhail Kapchits
NPI 1467447235
$14,309.11
in general payments reported to CMS, 2019-2025
69 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,203 · 2020: $1,637 · 2021: $2,244 · 2022: $2,175 · 2023: $2,275 · 2024: $2,008 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,030 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,030.31 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,101.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,847.98 | 2019-2025 | Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $1,209.23 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $788.76 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $646.79 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $615.67 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $506.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.60 | 2019-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $443.45 | 2019-2021 | |
| Medtronic, INC. | $443.44 | 2021-2025 | Cg Future, Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $431.52 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.02 | 2021-2025 | |
| Amgen INC. | $307.05 | 2020-2025 | Repatha, Repatha |
| Abbott Laboratories | $295.25 | 2019-2025 | Aveir, Infinity |
| Amarin Pharma, INC. | $278.64 | 2019-2023 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Kapchits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.